Atherosclerosis · 2026
The COPI coatomer influences LDL receptor activity, hepatic lipid storage, and apoB secretion.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Panteloglou Grigorios, Robert Jérôme, Smit Marieke, Huijkman Nicolette, Kloosterhuis Niels, Law Christopher S, Woods Brian, Othman Alaa, Kleber Marcus E, Delgado Graciela E, Tarugi Patrizia, Lone Museer A, Wolters Justina Clarinda, Rimbert Antoine, Kerksiek Anja, Lütjohann Dieter, Rohrer Lucia, Zanoni Paolo, Kakava Sofia, Häusler Stephanie, Schlumpf Eveline, Futema Marta, Humphries Steve E, Chou Janet, März Winfried, Geha Raif S, Shum Anthony K, Kuivenhoven Jan Albert, van de Sluis Bart, von Eckardstein Arnold
Аннотация
BACKGROUND AND AIMS: Decreased removal and increased production of apolipoprotein B (apoB) containing lipoproteins cause hypercholesterolemia, a major causal risk factor of atherosclerotic cardiovascular disease. By a genome-wide siRNA screen, we previously identified subunits of the Coat protein I (COPI) complex to limit low density lipoprotein (LDL) uptake into Huh-7 hepatocarcinoma cells. This study investigated the underlying mechanism and the role of impaired COPI function for hypercholesterolemia.
METHODS: Targeted loss of function experiments in vitro as well as genetic association studies in humans and three mouse models with mutated or disrupted COPI genes were performed.
RESULTS: Silencing of COPA, COPB1, COPB2, ARCN1, COPG1, and COPZ1 in Huh-7 cells resulted in decreased uptake of LDL and aberrant glycosylation and reduced cell surface abundance of the LDL receptor (LDLR) as well as increased apoB secretion and cellular lipid storage. Single nucleotide polymorphisms of ARCN1 were associated with lower ARCN1 expression and higher levels of LDL-cholesterol. While patients and mice carrying rare immunopathogenic missense variants of the WD40- or appendage domains of COPA and COPG1, respectively, had normal LDL-cholesterol levels, rare variants altering other domains of these proteins were enriched among patients with hypercholesterolemia. The hepatic knockdown of Copg1 increased the concentrations of nonHDL-cholesterol in plasma and triglycerides in the liver of mice.
CONCLUSIONS: The COPI coatomer regulates LDLR activity and apoB secretion as well as hepatic lipid content. Deficiency of Copg1 in mice and some but not all rare damaging COPI gene variants in humans are associated with higher LDL-cholesterol levels.
METHODS: Targeted loss of function experiments in vitro as well as genetic association studies in humans and three mouse models with mutated or disrupted COPI genes were performed.
RESULTS: Silencing of COPA, COPB1, COPB2, ARCN1, COPG1, and COPZ1 in Huh-7 cells resulted in decreased uptake of LDL and aberrant glycosylation and reduced cell surface abundance of the LDL receptor (LDLR) as well as increased apoB secretion and cellular lipid storage. Single nucleotide polymorphisms of ARCN1 were associated with lower ARCN1 expression and higher levels of LDL-cholesterol. While patients and mice carrying rare immunopathogenic missense variants of the WD40- or appendage domains of COPA and COPG1, respectively, had normal LDL-cholesterol levels, rare variants altering other domains of these proteins were enriched among patients with hypercholesterolemia. The hepatic knockdown of Copg1 increased the concentrations of nonHDL-cholesterol in plasma and triglycerides in the liver of mice.
CONCLUSIONS: The COPI coatomer regulates LDLR activity and apoB secretion as well as hepatic lipid content. Deficiency of Copg1 in mice and some but not all rare damaging COPI gene variants in humans are associated with higher LDL-cholesterol levels.